Pallas Health vs IVIM Health: clinician choice or review-backed program
Quick verdict: Pallas Health is best when you want a clinician to choose between FDA-approved pens and a per-patient compounded option in one intake, while IVIM Health stands out for unusually strong third-party ratings and a proprietary GLP-1 ID protocol. This comparison frames Pallas Health vs IVIM Health across pricing, medication options, clinical approach, trust signals, and logistics so you can decide which matches your priorities.
Start Pallas intake and see clinician options
Pallas Health vs IVIM Health: pricing and fees
Both platforms offer compounded GLP-1 options but differ in starting prices and fee structure. Pallas Health lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks, a $199/month average; compounded tirzepatide starts $179 first month, then $897 every 12 weeks, a $299/month average. Pallas also offers brand-name Wegovy, Ozempic, Zepbound and Mounjaro as cash-pay options with published monthly figures. Pallas bundles provider care, check-ins and messaging into an all-in plan price with no membership fee.
IVIM pricing snapshot
IVIM Health advertises a lower advertised starting figure for compounded semaglutide and promotional offers. Published details note semaglutide at $75/month and tirzepatide at $133/month plus a $74.99/month program fee in captured landing text, and IVIM promotional language includes a free month membership with code GIFT75. IVIM also highlights a no-obligation free consultation valued at $75. IVIM’s FAQ states a $99 first month and $174/month ongoing in other captured statements; confirm current figures at checkout since multiple published numbers appear in the source.
Claim IVIM free consult and GIFT75 offer
Medication options: brand-name availability versus compounded focus
Pallas Health provides both FDA-approved brand-name GLP-1s and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. IVIM Health focuses on compounded formulations and does not offer brand-name pens in the captured materials. Both sources include the regulatory qualifier that compounded medications are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality.
Clinical oversight and protocol differences
Pallas emphasizes a US-licensed clinician review and clinician selection between brand and compounded routes in a single intake, with provider care included in the plan price and asynchronous care in most states. IVIM highlights a proprietary GLP-1 ID protocol and clinician-guided titration it says can accelerate outcomes by up to 40% compared to another published GLP-1 trial; that 40% figure is IVIM’s protocol claim and not an independent head-to-head result. IVIM also notes weekly dose adjustments and clinician supervision tied to their protocol.
Trust signals and third-party validation
IVIM Health reports unusually strong third-party verification: a 4.9-star rating on both Google and Trustpilot, which the source presents as a standout satisfaction signal. Pallas lists LegitScript Healthcare Merchant Certification and published clinical disclosures as its verification signals. Use these different trust markers as part of your selection criteria.
Shipping, logistics and availability
Pallas advertises free expedited and discreet shipping on every plan and notes that compounded medications are prepared by US-licensed compounding pharmacies. Pallas is 100% online and asynchronous in most states, though a video visit is required in seven states plus Washington, D.C. IVIM’s materials note that compounded medications are prepared by independent licensed compounding pharmacies, that products may differ in appearance from images, and that services are not available in all states. Both reiterate that compounded drugs are not FDA-approved and carry specific regulatory considerations.
| Criteria | Pallas Health | IVIM Health |
|---|---|---|
| Starting price (captured) | $139 first month for compounded semaglutide | $75/mo advertised; code GIFT75 for free month |
| Medication types | Brand-name GLP-1s and US-compounded options | Compounded semaglutide and tirzepatide only in captured info |
| Provider care | Clinician review, check-ins, messaging included | No-obligation free consult; clinician-guided GLP-1 ID protocol |
| Third-party validation | LegitScript Healthcare Merchant Certified | 4.9 stars on Google and Trustpilot |
| Shipping and logistics | Free expedited discreet shipping; asynchronous in most states | Program fee applies; availability not in all states |
Explore Pallas plans and clinician review
How to choose: key decision points
Decide by weighing these distinctive differences. If you want the option of an FDA-approved brand-name pen alongside a clinician-personalized compounded alternative in one intake and an all-in price that includes provider care, Pallas Health is aligned with that priority. If you prioritize external satisfaction signals and a structured proprietary protocol with a no-obligation free consult and promotional free-month options, IVIM Health foregrounds those strengths.
Start IVIM free consult and learn GLP-1 ID
Pallas Health vs IVIM Health: final thoughts
Both providers work with compounded GLP-1s and require clinician assessment. Pallas combines brand-name and compounded options with an all-in pricing model and LegitScript certification. IVIM emphasizes dual 4.9-star external ratings, a proprietary GLP-1 ID protocol, and promotional entry offers. Review the pricing, clinician approach, verification signals and availability details captured above before deciding on Pallas Health vs IVIM Health.
Choose Pallas Health if you want a clinician to choose between brand-name GLP-1 pens and a US-compounded option in one intake, with provider care bundled into plan pricing. Choose IVIM Health if third-party ratings and a structured GLP-1 ID protocol with a free consultation and promotional free-month code matter more to you.